This table lists all the major pharma collaborations, acquisitions and mergers agreed during February 2014.
For an indepth analysis of these deals, read ‘Pharma deals during February 2014’
|
Licensor acquired / licensee acquirer |
Deal type |
Product / technology |
Headline ($m) |
| Forest Laboratories / Actavis | Company acquisition | Speciality pharma with strong CNS portfolio | 25,000 |
| Ablynx / Merck & Co | Collaboration | Nanobody candidates to target “immune checkpoint modulators” | 2,331 |
| Cadence Pharmaceuticals / Mallinckrondt | Company acquisition | Ofirmev (acetaminophen) for pain | 1,300 |
| Adcock Ingram / CFR Pharmaceuticals | Acquisition termination | South African generics company | 1,225 |
| Medpace / Cinven | Acquisition – majority shareholding | US mid-sized CRO with global presence | 915 |
| Cellectis / Servier | Licence | Product candidates for solid tumours, UCART19 (allogenic CAR-T) for leukaemia and lymphomas (6 candidates in total) | 850 |
| PreCision Dermatology / Valeant Pharmaceuticals | Company acquisition | Medical dermatological products | 500 |
| Crescendo Bioscience / Myriad Genetics | Company acquisition | Medical diagnostic tool for autoimmune diseases | 270 |
| Discuva / Roche | Collaboration | Antibiotics to target multi-drug resistant Gram negative bacteria | 201 |
| Ardelyx (formerly Nteryx) / Sanofi | Licence1 | NaP2b inhibitor programme for ESRD2 and CKD3 | 198 |
| Zosano (formerly Macroflux) / Novo Nordisk | Development | Semaglutide once weekly, ZP Patch Technology | 115 |
| Andromeda / Teva Pharmaceutical Industries | Licence termination | DiaPep277 for type 1 diabetes patients | 72 |
| Manchester Pharmaceuticals / Retrophin | Company acquisition | Rare disease company with marketed products in US (Chenodal to treat CTX4) | 63 |
| Apricus Biosciences (formerly NexMed) / Recordati | Licence | Vitaros topical treatment for erectile dysfunction | 51 |
| Abide Therapeutics / Celgene | Option and equity investment | Inflammatory and immunology target for catalytic of serine hydrolases for CNS signalling | 50 |
| 4-Antibody AG / Aegenus | Company acquisition | Retrocyte Display technology platform | 40 |
| UDG Healthcare / Professional Compounding Centers of America | Company acquisitions | UDG subsidiaries : The Specials Laboratory Holdings, Craig & Hayward, Arjun Products | 39 |
| Novo Nordisk / Innate Pharma | Licence with equity partial payment | Phase II ready Anti-NKG2A antibody “immune checkpoint inhibitor” | 30 |
| Servier / MacroGenics | Option exercise | MGD006, a DART-based product candidate for haematological malignancies | 15 |
| Forest Labs / Hospira (via Mayne Pharma) | Acquisition products | Esgic, ESGIC PLUS, Lorcet, LORCET PLUS – portfolio of pain products | 12 |
1. Co-promotion rights in US
2. Endstage renal disease
3. Chronic kidney disease
4. Cerebrotendinous xanthomatosis